infusio mannitoli 10 imuna
imuna pharm, a.s., slovensko - manitol - 76 - infundibilia
infusio mannitoli 20 imuna
imuna pharm, a.s., slovensko - manitol - 76 - infundibilia
mannitol 10% w/v intravenous infusion b.p., bieffe
bieffe medital s.p.a., taliansko - manitol - 76 - infundibilia
mannitol fresenius kabi 20 %
fresenius kabi s.r.o., Česká republika - manitol - 76 - infundibilia
mannitol 10 % baxter-viaflo
baxter slovakia s.r.o., slovensko - manitol - 76 - infundibilia
mannitol 20% w/v intravenous infusion b.p., bieffe
bieffe medital s.p.a., taliansko - manitol - 76 - infundibilia
fibclot 1,5 g
laboratoire français du fractionnement et des biotechnologies - Ľudský fibrinogén - 75 - substitutio sanguinis (a krvnÉ derivÁty)
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karcinóm, šquamózna bunka - antineoplastické činidlá - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
prepandrix
glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) ako použitý kmeň (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vakcíny - aktívna imunizácia proti podtypu h5n1 vírusu chrípky-a. tento údaj je založený na immunogenicity údaje zo zdravých subjektov, od veku 18 rokov a ďalej po podaní lieku dve dávky vakcíny pripravené s podtypu h5n1 kmene. prepandrix by mali byť použité v súlade s oficiálne usmernenie.
výskumný ústav včelařský, s. r. o., dol 94, 252 66 libčice nad vltavou, Česká republika.